Every time we care for a single person we make the whole world better...
Every time we care for a single person we make the whole world better...
and limited treatment options. We focus on oncology and rare diseases. We strive to bring meaningful therapeutic innovation to patients in need, no matter how rare their disease might be.
At Pierre Fabre Pharmaceuticals, we are building a company where innovation is rooted in partnership and mutual purpose: to improve the lives of people living with cancer and rare diseases. That means healthcare professionals are our trusted partners, science and nature are our sources of inspiration, and long-term relationships with researchers fuel our innovation.
We help patients live better by designing and developing therapeutic solutions. We build and nurture strong relationships with patients, caregivers, and patient organizations and collaborate with them to create best-in-class patient education and programs. We capture real-world evidence in all our indications, so we better understand how our medicines affect a broader set of patients. By keeping the patient voice front and center, we address the areas of highest unmet need and focus on delivering long-term value for patients.
Our parent company
We are the US pharmaceutical subsidiary of Pierre Fabre Laboratories. A global healthcare company for more than 60 years, Pierre Fabre Laboratories operates in 43 countries, with more than 10,000 employees and over $3 billion in revenue. The medical care division focuses on oncology, dermatology, rare diseases, primary care, and family health.
Pierre Fabre Laboratories is a purpose-driven company that strives to benefit society as a whole, encompassing healthcare, pharmaceutical ethics, and climate transition. Our focus on long-term value stems from our unique ownership structure: the company's majority shareholder is the Pierre Fabre Foundation, a government-recognized public-interest foundation that works to improve access to quality medicines and healthcare in Africa and Southeast Asia.
Every time we innovate to help each person live better...
Every time we repay nature for her treasures...
Every time we share the fruit of our efforts with those working and living beside us...
Every time the Pierre Fabre Foundation improves access to healthcare for those most in need...
Every time we care for a single person, we make the whole world better...
Partnerships and Pipeline
Every time we innovate to help each person live better...
Our focus is breakthrough therapies for diseases with high unmet needs, especially in oncology and rare diseases. We are actively identifying potential therapies to in-license and complement our growing pipeline.
As part of Pierre Fabre Laboratories, we bring six decades of worldwide experience in pharmaceutical commercialization, while our agile corporate structure enables us to develop and implement at biotech speed. Most of all, we emphasize creating long-term value for patients and society.
We build our pipeline through both research and development (R&D) and business development and licensing (BD&L). In both domains, oncology is a priority focus, accounting for over 80% of total investment.
Our current portfolio consists of one commercial product, one product in FDA review, one product in Phase II development, and two products in Phase I development.
Disease Area:
Hematology
Indication:
Relapsed or refractory Epstein-Barr virus+ post-transplant lymphoproliferative disorder (EBV+ PTLD)
Development Partner:
Registration
Development
Partner:
Disease Area:
Genetic Disorder
Indication:
Hypohidrotic ectodermal dysplasia (XLHED)
Development Partner:
Phase II
Development
Partner:
Disease Area:
Solid Tumor
Indication:
NRAS mutant melanoma
Development Partner:
Phase I
Development
Partner:
Disease Area:
Solid Tumor
Indication:
Non-small cell lung cancer (NSCLC) with mutation or amplification of MET
Phase I
Leadership
Experienced Leadership for Bold Pursuits
Collectively, we bring a strong track record in development, operations, and commercialization, across multiple platforms including biologics, targeted therapies, and cell therapies. We work together to channel our experience and make a difference for patients.
Chief Executive Officer
General Counsel and Compliance Officer
Medical Affairs
Mature Brands
Technical Operations
Finance
Business Operations
Commercial and Business Development
Value and Access
Regulatory Affairs and Pharmacovigilance
Patient Affairs
News
Tabelecleucel
Updated results of Phase III ALLELE Study presented at ASH annual meeting confirm efficacy, safety, and durability of novel allogeneic cell therapy Tabelecleucel in relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD)
07 December 2024
PFL-002 / VERT-002
Pierre Fabre Laboratories announce first patient dosed in Phase I/II clinical trial of PFL-002/VERT-002, an innovative targeted therapy intended to treat non-small cell lung cancer with MET alterations
24 October 2024
Tabelecleucel
Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel Biologics License Application for treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease with U.S. FDA
20 May 2024
Exarafenib
Kinnate Biopharma Inc. sells its investigational pan-RAF inhibitor, Exarafenib, to Pierre Fabre Laboratories
1 March 2024
Tabelecleucel
Atara Biotherapeutics and Pierre Fabre Laboratories announce publication of Phase III ALLELE Tabelecleucel Data in The Lancet Oncology
31 January 2024
Pierre Fabre
Foundation Medicine announces collaboration with Pierre Fabre Laboratories to develop companion diagnostics in non-small cell lung cancer
15 November 2023
Tabelecleucel
Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America
3 November 2023
Pierre Fabre
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
25 September 2023
PFL-002 / VERT-002
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy candidate for patients suffering from non-small cell lung cancer with MET alteration
12 September 2023
ER004
Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED
15 November 2021